Regorafenib monohydrate

• CAT Number: I000138
• CAS Number: 1019206-88-2
• Molecular Formula: C₂₁H₁₇ClF₄N₄O₄
• Molecular Weight: 500.83
• Purity: ≥95%
• Synonyms: 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide;hydrate
• Target: Autophagy
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• InChI: InChI=1S/C21H15ClF4N4O3.H2O/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26;/h2-10H,1H3,(H,27,31)(H2,29,30,32);1H2
• InChIKey: ZOPOQLDXFHBOIH-UHFFFAOYSA-N
• SMILES: CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F.O

Regorafenib monohydrate（Cat No.:I000138）is a multi-kinase inhibitor that targets various signaling pathways involved in tumor growth and angiogenesis, including VEGFR, PDGFR, KIT, and RAF kinases. It disrupts both tumor proliferation and the formation of blood vessels that support tumor growth, making it effective in treating cancers such as metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma. Regorafenib’s broad-spectrum activity against multiple kinases has made it a critical compound in oncology research, offering insights into targeted therapies for advanced, treatment-resistant cancers.

Reference

[1]. Wilhelm SM, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 2011, 129(1), 245-255.
[2]. Heng DY, et al. Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol, 2010, 2(1), 39-49.
[3]. Carr BI, et al. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol, 2013, 228(2), 292-297.